HighTower Advisors LLC Boosts Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

HighTower Advisors LLC grew its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 461.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 148,605 shares of the company’s stock after purchasing an additional 122,154 shares during the quarter. HighTower Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $2,675,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. FMR LLC increased its holdings in Teva Pharmaceutical Industries by 49.5% during the third quarter. FMR LLC now owns 62,740,763 shares of the company’s stock worth $1,130,589,000 after buying an additional 20,762,226 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd raised its holdings in shares of Teva Pharmaceutical Industries by 6.8% in the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock worth $621,337,000 after purchasing an additional 2,204,623 shares during the period. Renaissance Technologies LLC lifted its stake in Teva Pharmaceutical Industries by 13.4% in the second quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock valued at $141,839,000 after purchasing an additional 1,031,400 shares during the last quarter. Truist Financial Corp grew its holdings in Teva Pharmaceutical Industries by 7.0% during the second quarter. Truist Financial Corp now owns 3,885,251 shares of the company’s stock valued at $63,135,000 after purchasing an additional 254,483 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Teva Pharmaceutical Industries by 237.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,377,517 shares of the company’s stock worth $60,863,000 after buying an additional 2,376,668 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Stock Down 1.8 %

TEVA opened at $16.50 on Friday. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. Teva Pharmaceutical Industries Limited has a one year low of $9.90 and a one year high of $19.31. The firm has a market capitalization of $18.69 billion, a P/E ratio of -19.41, a price-to-earnings-growth ratio of 1.04 and a beta of 0.79. The company has a fifty day moving average price of $17.51 and a 200-day moving average price of $17.39.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on TEVA shares. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. UBS Group increased their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Finally, Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares in the company, valued at $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.55% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.